JNJ
The headline: still standing tall
Johnson & Johnson opened 2026 with a quarter that quietly did the hard thing: beat expectations while one of its old crown jewels keeps losing shine. The company posted adjusted EPS of $2.70, ahead of the $2.68 Wall Street was looking for, and revenue of $24.1 billion versus a $23.61 billion forecast.
The Stelara problem is real — but not fatal
If you’ve been following J&J, you know the Stelara story is the corporate version of trying to run a marathon with one shoelace untied. Biosimilar competition is pressuring the drug, and that’s not a tiny side quest — it’s a meaningful headwind. But this quarter shows the rest of the business is doing enough to keep the ship moving in the right direction.
Why investors should care
A beat like this doesn’t magically erase patent cliffs or biosimilar erosion. But it does tell you J&J still has some juice across its portfolio, which matters a lot for a mega-cap healthcare name that investors often treat like a defensive anchor.
- Earnings came in slightly ahead of consensus
- Revenue also topped estimates
- The broader portfolio helped cushion Stelara-related pressure
Big picture
For J&J shareholders, this is the kind of quarter that says, “yes, there are bruises, but the engine still runs.” In a market that loves drama, steady resilience can be its own kind of superpower.